Status and phase
Conditions
Treatments
About
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
ECOG score of physical condition is 0 ~ 1;
The expected survival time is at least 3 months;
Prostatic adenocarcinoma confirmed by histological or cytological examination, with no indication of neuroendocrine or small-cell characteristics;
Fasting blood glucose level is: 3.9~6.1mmol/L;
The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) :
According to the researcher's judgment, it can comply with the experimental scheme;
Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
18 participants in 1 patient group
Loading...
Central trial contact
shijuan kuang, Master; Yuya Wang, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal